Table 3:

Prognostic indicators for patients with B-cell ALL and T-cell ALL

	Patients with B-cell ALL	Patients with T-cell ALL
Clinical
Favourable	Age 1–10 years and leucocyte count <50 × 109/L, Caucasian or Asian, CNS1 disease status	CNS1 disease status
Intermediate	Age ≥10 years, leucocyte count 50–100 × 109/L, black race, CNS2 disease status, testicular leukaemia	CNS2 or CNS3 disease status, testicular leukaemia
Unfavourable	Age <1 year, leucocyte count >100 × 109/L, native American or Hispanic race, CNS3 disease status	Leucocyte count >200 × 109/L*
Biological
Favourable	ETV6-RUNX1-type, hyperdiploidy (51–67 chromosomes; DNA index ≥1·16)	NOTCH1 mutation, FBXW7 mutation
Intermediate	ETV6-RUNX1-like, TCF3-PBX1, DUX4-ERG, PAX5, ZNF384-rearranged, iAMP21	Early T-cell precursor ALL
Unfavourable	BCR-ABL1-type, BCR-ABL1-like, KMT2A-rearranged, MEF2D-rearranged, hypodiploid (<44 chromosomes)	RAS mutation, PTEN mutation, lack of biallelic TRG rearrangements
Response to chemotherapy (minimal residual disease)
Favourable	Day 8 blood minimal residual disease <10−4, day 15 or day 19 bone marrow minimal residual disease <10−2, end of induction bone marrow minimal residual disease <10−4	End of induction bone marrow minimal residual disease <10−4
Intermediate	End of induction bone marrow minimal residual disease from 10−4 to 10−2	End of induction bone marrow minimal residual disease ≥10−4 and end of consolidation minimal residual disease ≥10−4 and <10−3
Unfavourable	End of induction bone marrow >1% blasts	End of consolidation bone marrow minimal residual disease ≥10−3

ALL=acute lymphoblastic leukaemia.

^*Not consistent.